Creative Planning
CASC

Creative Planning’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Creative Planning’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-35
Closed – – 4468
2017
Q2 		$0 Hold
35
– – ﹤0.01% 5015
2017
Q1 		$0 Hold
35
– – ﹤0.01% 5069
2016
Q4 		$0 Sell
35
-84
-71% -$543 ﹤0.01% 5016
2016
Q3 		$1K Buy
119
+83
+231% +$589 ﹤0.01% 4516
2016
Q2 		$0 Hold
36
– – ﹤0.01% 4638
2016
Q1 		$0 Hold
36
– – ﹤0.01% 4692
2015
Q4 		$0 Sell
36
-4,167
-99% -$71.8K ﹤0.01% 4719
2015
Q3 		$69K Buy
+4,203
New +$86.2K ﹤0.01% 1827
2015
Q2 		– Sell
-36
Closed – – 3667
2015
Q1 		$0 Hold
36
– – ﹤0.01% 4522
2014
Q4 		$0 Hold
36
– – ﹤0.01% 4459
2014
Q3 		$0 Sell
36
-111
-76% -$1.7K ﹤0.01% 4257
2014
Q2 		$3K Buy
147
+111
+308% +$1.96K ﹤0.01% 3449
2014
Q1 		$1K Sell
36
-1,341
-97% -$22K ﹤0.01% 3560
2013
Q4 		$15K Hold
1,377
– – ﹤0.01% 2369
2013
Q3 		$17K Sell
1,377
-56
-4% -$589 ﹤0.01% 2193
2013
Q2 		$13K Buy
+1,433
New +$18.4K ﹤0.01% 2164

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

Creative Planning's CASC Position: Q3 2017 in Review

Creative Planning sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 35 shares.

Creative Planning first reported a position in CASC in Q2 2013 and held it in 16 quarters. The position peaked at $69K in Q3 2015. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • Creative Planning reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Creative Planning sold 35 Cascadian Therapeutics, Inc. shares in Q3 2017.
  • Creative Planning first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
  • Creative Planning's Cascadian Therapeutics, Inc. position peaked at $69K in Q3 2015.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.